Clinical trials: Anterior Ischemic Optic Neuropathy
Ischemic Optic Neuropathy
Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
To follow all patients enrolled in the original Ischemic Optic Neuropathy Decompression Trial (IONDT) to determine (1) the incidence of non-arteritic ischemic optic neuropathy (NAION) in the second eye, (2) changes in visual…
- Trial name
- NCT00000126
- Testing
- Surgery
- Where
- 24 sites in United States
- Sponsor
- National Eye Institute (NEI)
Giant Cell Arteritis, Optic Ischaemic Neuropathy
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
AION is the main cause of blindness in patients with GCA. High dose steroid is the reference treatment of this condition, but medical unmet need remains.
- Trial name
- TOCIAION (NCT04239196)
- Testing
- tocilizumab and IV steroids combination, IV steroids combination alone
- Where
- 10 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy
Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
Giant cell arteritis (GCA) is an inflammation of the blood vessels. A dangerous complication is sudden vision loss due to insufficient blood supply to the optic nerve.
- Conditions
- Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy
- Trial name
- VISION-GCA (NCT07206238)
- Testing
- Positron Emission Tomography / Magnetic Resonance Imaging
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Controlled Hypotension for Nasal Surgeries
Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During Rhinoplasty
This randomized controlled trial aims to evaluate the effects of two different mean arterial pressure (MAP) targets during controlled hypotension on ocular perfusion and optic nerve head microvasculature in patients undergoing…
- Trial name
- NCT07832305
- Testing
- Lower MAP Target Strategy (50-60 mmHg), Higher MAP Target Strategy (60-70 mmHg)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Hitit University
Ischemic Optic Neuropathy
Ischemic Optic Neuropathy Decompression Trial (IONDT)
To assess the safety and efficacy of optic nerve sheath decompression surgery for non-arteritic ischemic optic neuropathy (NAION).
- Trial name
- NCT00000127
- Testing
- Optic Nerve Sheath Decompression Surgery
- Sponsor
- National Eye Institute (NEI)
Nonarteritic Anterior Ischemic Optic Neuropathy
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION.
- Trial name
- NCT03547206
- Testing
- RPh201 Cohort A, RPh201 Cohort B
- Where
- 15 sites in United States
- Volunteers
- 165 people
- Sponsor
- Regenera Pharma Ltd
Anterior Ischemic Optic Neuropathy
Effect of EECP on Anterior Ischemic Optic Neuropathy
Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.
- Trial name
- AION (NCT01768260)
- Testing
- Enhanced external counterpulsation, Aspirin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Non-arteritic Anterior Ischemic Optic Neuropathy
Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy
Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision.
- Trial name
- NCT00813059
- Testing
- Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Mount Sinai Hospital, Canada
Nonarteritic Anterior Ischemic Optic Neuropathy
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION).
- Trial name
- NCT00432393
- Testing
- levodopa-carbidopa
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Non Arthritic Anterior Ischemic Optic Neuropathy
Neurotomy of Optic Nerve in Non-Arthritic Anterior Ischemic Optic Neuropathy
Non-arthritic anterior ischemic optic neuropathy is the most common cause of sudden visual loss due to optic nerve involvement in patients above 50 years old.
- Trial name
- NCT00372021
- Testing
- optic nerve neurotomy
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Non-Arteritic Anterior Ischemic Optic Neuropathy
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION.
- Trial name
- NCT07453888
- Testing
- Cenegermin, Vehicle
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 272 people
- Sponsor
- Dompé Farmaceutici S.p.A
Obstructive Sleep Apnea (OSA), Ischemic Optic Neuropathy/Optic Nerve Stroke
Optic Nerve Injury in Obstructive Sleep Apnea Patients
Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries.
- Trial name
- NCT06748703
- Testing
- CPAP Treatment
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanjing Medical University
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Blindness
Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry
This is a study to focus on the feasibility of using a monitor which may signal loss of visual function intraoperatively.
- Trial name
- NCT01219569
- Testing
- propofol, Sevoflurane
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
NA-AION Risk Factors: New Perspectives
The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION.
- Trial name
- NARROW (NCT05305079)
- Where
- 20 sites in United States, Australia and 7 more
- Volunteers
- 179 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy
Patients diagnosed with NAION within 14 days of onset were included. Patients were randomized into 3 groups. Group 1 or control consisted of 30 patients who received gelatinous capsules filled with sugar as placebo.
- Trial name
- NAION (NCT02439866)
- Testing
- Intravenous methylprednisolone, normobaric oxygen with face mask
- Where
- Iran
- Volunteers
- 90 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Triamcinolone Acetonide, Optic Neuropathy, Ischemic
Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION
NAION produces an ischemic insult in the optic nerve head presumably due to the hypoperfusion of the short ciliary arteries that supply it.
- Trial name
- NCT02329288
- Testing
- Triamcinolone Acetonide
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists.
- Trial name
- NCT07846956
- Testing
- GLP-1 Receptor Agonist Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Istanbul Saglik Bilimleri University
Non-arteritic Ischemic Optic Neuropathy
Peripapillary and Macular Vascular Changes of Unilateral Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study
This series aims at studying the peripapillary and macular vascular changes in subjects with unilateral anterior ischemic optic neuropathy via Optical Coherence Tomography Angiography (OCTA).
- Trial name
- NCT06031350
- Testing
- Optical Coherence Tomography Angiography
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Omar Said